Kybernin P (Antithrombin Iii)

• Kybernin P, an antithrombin concentrate, acts on the coagulation cascade to restore antithrombin activity.
• Hereditary antithrombin deficiency: restores antithrombin levels and reduces risk of spontaneous clotting.
• Prevention of thromboembolic events in surgical or high‑risk patients: provides prophylactic antithrombin activity to lower peri‑operative clot risk.
• Treatment of acute thrombotic episodes in antithrombin‑deficient patients: supports anticoagulation during active clot management.

• Antithrombin III is a serine‑protease inhibitor that binds and inactivates thrombin (factor IIa) and other activated clotting factors such as factor Xa, IXa, XIa, and XIIa. By replenishing circulating antithrombin, Kybernin P reduces enzymatic activity within the coagulation cascade, thereby decreasing fibrin formation and limiting propagation of thrombi. The restored inhibition also attenuates downstream amplification loops, contributing to a more stable hemostatic balance during periods of increased thrombotic risk.

Kybernin P may be associated with infusion‑related and systemic adverse reactions.

Common Side Effects

• Injection site reactions: erythema, pain, or swelling at the infusion site.
• Transient fever: mild temperature elevation occurring shortly after administration.
• Nausea: occasional feeling of queasiness without vomiting.
• Headache: mild to moderate headache reported during treatment.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction with respiratory distress, urticaria, or hypotension.
• Thrombotic microangiopathy: rare syndrome characterized by thrombocytopenia and microvascular thrombosis.
• Hemolysis: uncommon destruction of red blood cells leading to anemia.

Prior to using Kybernin P, clinicians should consider several safety and handling precautions.

• Patient assessment: evaluate antithrombin levels and coagulation status before initiation.
• Bleeding risk: monitor for signs of bleeding, especially in patients on concurrent anticoagulants.
• Renal function: adjust monitoring in patients with impaired renal clearance.
• Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited.
• Concomitant therapy: avoid simultaneous use with heparin products unless antithrombin levels are closely monitored.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other agents that affect coagulation or antithrombin activity.

Major Interactions (Avoid)

• Heparin: concurrent use may cause excessive anticoagulation due to enhanced heparin activity.
• Direct thrombin inhibitors: combined effect may increase bleeding risk.
• Antifibrinolytics: may counteract antithrombin’s anticoagulant effect.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR as antithrombin replacement can alter vitamin K antagonist response.
• Aspirin or NSAIDs: increased risk of gastrointestinal bleeding; observe for signs of hemorrhage.
• Oral contraceptives: potential additive effect on clotting; assess thrombotic risk.